1

PRODUCTION OF AFFORDABLE CHEMOTHERAPY
M. Sjamsul Arifin President Director of PT. Kimia Farma. Tbk

2

AGENDA ….
1. 2. 3. 4.

GLOBAL CANCER MARKET INDONESIAN PHARMA MARKET KF EFFORT SUMMARY

GLOBAL CANCER ……..
Market Size: 65 billion USD Growth Rate: 23% Third biggest therapy class Out of 82 blockbuster drugs 7 are anticancer*
*MabThera, Glivec, Eloxatin, Gemzar, Casodex, Taxotere & Zometa
3
Source: Business Wire – , 2008 – IMS Health

CANCER INCIDENCE GLOBALLY ….
4

18,30% 17,90% 14,60% 12,20% 11,50%

5,50%

5,20% 3,60% 3,40% 2,30% 2,20% 1,80% 1,60%

TOP 5 CANCERS GLOBALLY BY GENDER …..
TOP 5 IN FEMALES

Breast

36.70% 17.30% 11.40% 8.90% 0.10%

Large Bowel Melanoma of Skin

TOP 5 IN MALES

Lung Non Hodgkins Lymphoma

Prostate

29.20% 18.50% 14.10% 12.90% 4.90%

Large Bowel

Lung Melanoma of Skin Non Hodgkins Lymphoma

5

UNIQUE THERAPHY BEHAVIOUR ……..

Note : 50% of growth is driven by New Drugs
6

7

INDONESIAN PHARMA MARKET ….

8

9

MARKET ANALYSIS ( Cancer Product ) …
10

Value : IDR Billions

RANK
1 2 3 4 5 6

COMPANY
LC MNC MNC LC LC MNC

2008
144 78 43 28 27 25

G%
(7.7) 35.2 5.9 36.8 4.2 (7.9 )

2007
156 58 40 20 26 28

G%
21.4 31.9 52.9 32.7 11.2 10.9

2006
156 44 27 15 23 25

Based on ITMA Data MAT Dec 2008

KF as a state Own Company …
11

¨

We have business from down stream to up stream :
5 Manufacturers ¤ 40 distributors ¤ 350 retail pharmacies ¤ 500 Medical representative
¤

¨

We also have many range of products & to serve many customers ( private sector & government sector )

KF EFFORT ….
12

q

q

q

KF will develop strategic products for Cancer & HIV AIDS KF will cooperation with national Insurance & Cancer Hospital KF will have a collaboration with:
q

q
q

Domestic Partner : BATAN Foreign Partner : Naprod & 3M

In future KF will build a Plant for developing Cancer & HIV products (already finished)

13

Prevention Cancer Therapeutics
1. 2. 3. 4.

Early Detection and Screening Diagnosis and Treatment Support and Rehabilitation Palliative Care

14

STRATEGYC PRODUCT FOR CANCER

LIST PRODUCT ONCOLOGY BY KF (NAPROD) ……..
No. Product Name
1 Napro-Tax 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Cisteen Cisteen Alltrex Alltrex Naprocil Naprodox Naprodox Nzytop Xifen Xifen Taceedo Taceedo 4-Epeedo-10 4-Epeedo-50 Abingem – 200 Abingem – 1 Gr

Active Pharma Ing
Paclitaxel 30 mg Cisplatin 10 mg Cisplatin 50 mg Methotrexate 50 mg Methotrexate 2.5 mg 5 - Fluourouracil 500 mg Doxorubicin 10 mg Doxorubicin 50 mg Etoposide 100 mg Tamoxifen 10 mg Tamoxifen 20 mg Cyclophosphamidie Docitaxel Docitaxel Epirubicin Epirubicin Gemcitabine inj Gemcitabine inj

Strenght
6 mg/ ml 1 mg / ml 1 mg / ml 25 mg /ml tablet 2.5 mg 100 mg / ml 2 mg / ml 2 mg / ml 20 mg / ml 10 mg / capsul 20 mg / capsul 500 mg 20 mg 80 mg 10 mg 50 mg 200 mg 1.000 mg

Pack size
vial 5 ml vial 10 ml vial 50 ml vial 2 ml 100 tab vial 10 mg vial 5 ml vial 25 ml vial 5 ml 10 x 10 cap 10 x 10 cap vial vial vial vial vial vial vial

15

16

17

To Produce Affordable Price
18

¨

To make copy product
¤ Cooperation

with Naprod (specialist oncology product) ¤ 18 SKU product chemoterapy ¤ Saving Cost ( 20 % – 50 % EP )
¨ ¨

Easy to get and avalailable in all provinces Quality guaranteed

P R I C E
19

C O M P A R A T I V E

Ingredient Epirubicin 10 mg

Brand Name 4-Epeedo-10 Epirubicin 4-Epeedo-50 Epirubicin Taceedo 20 Taxotere Brexel Taceedo 80 Taxotere Brexel Napro-Tax 30 mg Taxol Paxus Naprodox 10 mg Doxorubicin Naprodox 50 mg Doxorubicin Abingem 200 Gemzar Abingem 1 gr Gemzar Cisteen 10 mg Cisplatin Cisteen 50 mg Cisplatin

Company Naprod Kompetitor Naprod Kompetitor Naprod Kompetitor A Kompetitor B Naprod Kompetitor A Kompetitor B Naprod Kompetitor A Kompetitor B Naprod Kompetitor A Naprod Kompetitor A Naprod Kompetitor A Naprod Kompetitor A Naprod Kompetitor A Naprod Kompetitor A

Price Ratio (%) 185.000 80 230.000 100 Price 900.000 1.130.000 1.100.000 2.250.830 1.400.000 3.500.000 6.941.780 4.300.000 700.000 1.334.800 907.500 120.000 154.000 550.000 696.850 500.000 617.272 2.400.000 2.935.545 50.000 69.300 215.000 290.000 80 100 49/79 100 100 50/81 100 100 52/72 100 100 78 100 79 100 81 100 82 100 72 100 74 100

Epirubicin 50 mg

Docetaxel 20 mg

Docetaxel 80 mg

Paclitaxel 30 mg

Doxorubicin 10 mg

Doxorubicin 80 mg

Gemcitabin 200 mg

Gemcitabin 1 g

Cisplatin 10 mg Cisplatin 50 mg

RATIONAL DRUG USE (WHO 2001)
20

q Patients q Doses q For q The

receive medicines appropriate to their clinical needs that meet their individual requirement. an adequate period of time lowest cost to them and their community

21

WHAT IS ….BIO-EQUIVALENT
22

GENERIC DRUG SUBSTITUTE REQUIREMENT …
23

Source : FDA Division of Bioequivalence

To Conduct Sinergy ….
24

¨

¨

¨ ¨

To support & supply government needs for Social Health Insurance To make co-operation with National Health Insurance Co-operation with Cancer Hospital Mutual benefit for government, health insurance corporate, hospitals and public to complete cancer treatments

25

SUMMARY …..
KF committed to launch chemotherapy product & affordable price q KF committed to assist government health program q Sinergy program with governmet, health insurance , hospitals for implementing of integrated cancer treatment
q

TEAM WORK …. ????

27

Thank You ….

Sign up to vote on this title
UsefulNot useful